Decahydroisoquinolines: Novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia

Neuropharmacology

Volumn 37, Issue 10-11, 1998, Pages 1211-1222

  O'Neill, Michael J ^a   Bond, Ann ^a   Ornstein, Paul L ^a   Ward, Mark A ^a   Hicks, Caroline A ^a   Hoo, Ken ^b   Bleakman, David ^a   Lodge, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NPS Pharmaceutical Inc   (United States)

Author keywords

AMPA antagonist; Cerebral ischemia; Gerbil; iGluR5; LY293558; LY377770; Neuroprotection

Indexed keywords

AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; GLUTAMATE RECEPTOR ANTAGONIST; ISOQUINOLINE DERIVATIVE; KAINIC ACID RECEPTOR ANTAGONIST; LY 377770; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN ISCHEMIA; CONFERENCE PAPER; CONTROLLED STUDY; ELECTROPHYSIOLOGY; GERBIL; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANIMALS; BRAIN ISCHEMIA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GERBILLINAE; ISOQUINOLINES; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; TIME FACTORS;

EID: 0032191984     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00134-8     Document Type: Conference Paper

References (61)

1. Anis, N.A., Berry, S.C., Burton, N.R., Lodge, D., 1983. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by TV-methyl aspartate. Br. J. Pharmacol. 79, 562-575.
2. Arvin, B., Moncada, C., Le Peillet, E., Chapman, A., Meldrum, B.S., 1992. GYKI 52466 blocks the increase in extracellular glutamate induced by ischaemia. NeuroReport 3, 235-238.
3. Barone, F.C., Feuerstein, G.Z., White, R.F., 1997. Brain cooling during transient focal ischemia provides complete neuroprotection. Neurosci. Biobehav. Rev. 21, 31-44.
4. Bleakman, D., Ballyk, B.A., Schoepp, D.D., Palmer, A.J., Bath, C.P., Sharpe, E.F., Woolley, M.L., Bufton, H.R., Kamboj, R.K., Tarnawa, I., Lodge, D., 1996a. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vivo: stereospecificity and selectivity profiles. Neuropharmacology 35, 1689-1702.
5. Bleakman, D., Schoepp, D.D., Ballyk, B., Bufton, H., Scharpe, E.F., Thomas, K., Ornstein, P.L., Kamboj, K., 1996b. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)]decahydroisoquinoline-3-carboxylic acid. Mol. Pharmacol. 49, 581-585.
6. Bleisch, T.J., Ornstein, P.L., Allen, N.K., Wright, R.A., Lodge, D., Schoepp, D.D., 1997. Structure activity studies of aryl-spaced decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 7, 1161-1166.
7. Boast, C.A., Gerhardt, S.C., Pastor, G., Lehmann, J., Ethienne, P.E., Liebmann, J., 1988. The N-methyl-D-aspartate antagonist CGS 19755 and CPP reduce ischaemic damage in gerbils. Brain Res. 442, 345-348.
8. Browne, S.E., McCulloch, J., 1994. AMPA receptor antagonists and local cerebral glucose utilisation in the rat. Brain Res. 641, 10-20.
9. Buchan, A.M., Pulsinelli, W.A., 1990. Hypothermia, but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J. Neurosci. 10, 311-316.
10. Bullock, R., Graham, D.I., Swanson, S., McCulloch, J., 1990. Neuroprotective effect of the AMPA receptor antagonist LY 293558 in focal ischaemia in the cat. J. Cereb. Blood Flow Metab. 14, 466-471.
11. Busto, R., Dietrich, W.D., Globus, M.Y.-T., Valdes, I., Scheinberg, P., Ginsberg, M.D., 1987. Small differences in the intraischemic brain temperature critically determine the extent of ishcemic neuronal injury, J. Cereb. Blood Flow Metab. 7, 729-738.
12. Busto, R., Dalton Dietrich, W.D., Globus, M.Y.-T., Ginsberg, M.D., 1989. Postischemic moderate hypothermia inhibits CA1 hippocampal ischemic neuronal injury. Neurosci. Lett. 101, 299-304.
13. Butcher, S.P., Bullock, R., Graham, D.I., McCulloch, J., 1990. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 21, 1727-1733.
14. Choi, D.W., Maulucci-Gedde, M., Kriegstein, A.R., 1987. Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 7, 357-368.
15. Choi, D.W., Koh, J.-Y., Peters, S., 1988. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8, 185-196.
16. Clarke, V.R.J., Ballyk, B.A., Hoo, K.H., Mandelzys, A., Pellizzari, A., Bath, C.P., Thomas, J., Sharpe, E.F., Davies, C.H., Ornstein, P.L., Schoepp, D.D., Kamboj, R.K., Collingridge, G.L., Lodge, D., Bleakman, D., 1997. A GluR5 kainate receptor that regulates inhibitory synaptic transmission in the hippocampus. Nature 389, 599-603.
17. Colbourne, F., Corbett, D., 1994. Delayed and prolonged post-ischemic hypothermia is neuroprotective in the gerbil. Brain Res. 654, 265-272.
18. Collingridge, G.L., Lester, R.A.J., 1989. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40, 143-210.
19. Corbett, D., Evans, S., Thomas, C., Wang, D., Jones, R.A., 1990. MK-801 reduced cerebral ischemic injury by inducing hypothermia. Brain Res. 514, 300-304.
20. Dietrich, W.D., Busto, R., Alonso, O., Globus, M.Y.-T., Ginsberg, M.D., 1993. Intraischemic but not postischemic brain hypothermia protects chronically following global forebrain ischemia in rats. J. Cereb. Blood Flow Metab. 13, 541-549.
21. Diemer, N.H., Jorgensen, M.B., Johansen, F.F., Sheardown, M., Honoré, T., 1991. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist NBQX. Acta Neurol. Scand. 86, 45-49.
22. Donevan, S.D., Rogawski, M.A., 1993. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10, 51-59.
23. Gill, R., 1994. The pharmacology of α-Amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc. Brain Metab. Rev. 6, 225-256.
24. Gill, R., Foster, A.C., Woodruff, G.N., 1987. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7, 3343-3349.
25. Gill, R., Nordholm, L., Lodge, D., 1992. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischemia model. Brain Res. 580, 35-43.
26. Gill, R., Lodge, D., 1995. The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischaemia. Neuropharmacology 33, 1529-1536.
27. Globus, M.Y.-T., Busto, R., Dietrich, W.D., Martinez, E., Valdes, I., Ginsberg, M.D., 1988. Effect of ischemia on in vivo release of striatal dopamine, glutamate and gamma-aminobutyric acid studied by intracerebral microdialysis. J. Neurochem. 51, 1455-1464.
28. Gotti, B., Benvides, J., MacKenzie, E.T., Scatton, B., 1990. The pharmacology of focal cortical ischaemia in the mouse. Brain Res. 522, 355-358.
29. Graham, S.H., Chen, J., Lan, J.Q., Simon, R.P., 1996. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J. Pharmacol. Exp. Ther. 276, 1-4.
30. Green, E.J., Pazos, A.J., Dietrich, W.D., McCabe, P.M., Schneiderman, N., Lin, B., Busto, R., Globus, M.Y.-T., Ginsberg, M.D., 1995. Combined postischemic hypothermia and delayed MK-801 treatment attenuates neurobehavioral deficits associated with transient global ischemia in rats. Brain Res. 701, 145-152.
31. Grotta, J.C., Picone, C.M., Ostrow, P.T., Strong, R.A., Earls, R.M., Yao, L.P., Rhoades, H.M., Dedman, J.R., 1990. CGS 19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. 27, 612-619.
32. Hayward, N.J., McKnight, A.T., Woodruff, G.N., 1993. Brain temperature and the neuroprotective action of enadoline and dizocilipine in the gerbil model of global-ischemia. Eur. J. Pharmacol. 236, 247-253.
33. Izumisawa, N., Kawakami, A., Ohata, T., Kanada, T., Okeda, R., 1995. YM90K, an AMPA antagonist, has no neurotoxic effects on cerebrocortical neurons in rats. Exp. Neurol. 134, 199-204.
34. Judge, M.E., Sheardown, M.J., Jacobsen, P., Honoré, T., 1991. Protection against post-ischemic behavioral pathology by the α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in the gerbil. Neurosci. Lett. 133, 291-294.
35. Koek, W., Woods, J.H., Winger, G.D., 1988. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245, 969-974.
36. Kurumaji, A., Nehls, D.G., Park, C.K., McCulloch, J., 1989. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 496, 268-284.
37. Le Peillet, E., Arvin, B., Moncada, C., Meldrum, B.S., 1992. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res. 571, 115-120.
38. Li, H., Buchan, A.M., 1993. Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab. 13, 933-939.
39. Lodge, D., Bond, A., O'Neill, M.J., Hicks, C.A., Jones, M.G., 1996. Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology 35, 1681-1688.
40. Narita, N., Hashimoto, K., Tomitaka, S.I., Minabe, Y., Yamazaki, K., 1997. YM90K, a selective alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonist, prevents induction of heat shock protein hsp-70 and hsp-70 mRNA in rat retrosplenial cortex by phencyclidine. Addict. Biol. 2, 47-56.
41. Nurse, S., Corbett, D., 1996. Neuroprotection after several days of mild, drug-induced hypothermia. J. Cereb. Blood Flow. Metab. 16, 474-480.
42. Olney, J.W., Labruyere, J., Price, M.T., 1990. Pathological changes induced in cerebrocortical neurons by phenyclidine and related drugs. Science 244, 1360-1362.
43. Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T., Sesma, M.A., 1991. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.
44. O'Neill, M.J., Hicks, C., Ward, M., 1996. Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia. Eur. J. Pharmacol. 310, 115-122.
45. Ornstein, P.L., Arnold, M.B., Augenstein, N.K., Lodge, D., Leander, J.D., Schoepp, D.D., 1993. (3SR,4aRS,6RS,8aRS)-6-[2-(1-H-Tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid. A structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med Chem. 36, 2046-2048.
46. Ornstein, P.L., Arnold, M.B., Allen, N.K., Leander, J.D., Tizzano, J.P., Lodge, D., Schoepp, D.D., 1995. (3SR,4aRS,6SR,8aRS)-6-[-(1-H-Tetrazol-5-yl) decahydroisoquinoline-3-carboxylic acid quinoline-3-carboxylic acid. A novel competitive, systemically active, NMDA and AMPA receptor antagonist. J. Med Chem. 38, 4885-4890.
47. Ornstein, P.L., Arnold, M.B., Allen, N.K., Bleisch, T., Borromeo, P.S., Lugar, C.W., Leander, J.D., Lodge, D., Schoepp, D.D., 1996a. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA antagonists. 1. Effects of stereochemistry, chain length and chain substitution. J. Med. Chem. 39, 2219-2231.
48. Ornstein, P.L., Arnold, M.B., Allen, N.K., Bleisch, T., Borromeo, P.S., Lugar, C.W., Leander, J.D., Lodge, D., Schoepp, D.D., 1996b. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA antagonists. 1. Effects of distal acid biosteric substitution, absolute stereochemical preferences, and in vivo activity. J. Med. Chem. 39, 2232-2244.
49. Park, C.K., McCulloch, J., Kang, J.K., Choi, C.R., 1992. Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat. Neurosci. Lett. 147, 41-44.
50. Patel, T.R., McCulloch, J., 1995. AMPA receptor antagonism attenuates MK-801-induced hypermetabolism in the posterior cingulate cortex. Brain Res. 686, 254-258.
51. Schoepp, D.D., Lodge, D., Bleakman, D., Leander, J.D., Tizzano, J.P., Wright, R.A., Palmer, A.J., Salhoff, C.R., Ornstein, P.L., 1995. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)]decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34, 1159-1168.
52. Sharkey, J., Ritchie, I.M., Butcher, S.P., Kelly, J.S., 1996. Comparison of the patterns of altered cerebral glucose utilisation produced by competitive and non-competitive NMDA receptor antagonists. Brain Res. 735, 67-82.
53. Sheardown, M.J., Nielson, E.O., Hansen, A.J., Jacobsen, P., Honoré, T., 1990. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuro-protectant for cerebral ischemia. Science 247, 571-574.
54. Sheardown, M.J., Suzdak, P.D., Nordholm, L., 1993. AMPA, but not NMDA, receptor anatagonism is neuroprotective in gerbil global ischaemia. Eur. J. Pharmacol. 236, 347-353.
55. Shimizu-Sasamata, M., Kawasaki-Yatsugi, S., Okada, M., Sakamoto, S., Yatsugi, S., Togami, J., Hatanaka, K., Ohmori, J., Koshiya, K., Usuda, S., Murase, K., 1996. YM90K: pharmacological characterization as a selective and potent α-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther. 276, 84-92.
56. Smith, S.E., Meldrum, B.S., 1992. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke 23, 861-864.
57. Watkins, J.C., Olverman, H.J., 1987. Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci. 10, 265-272.
58. Xue, D., Huang, Z.-G., Smith, K.E., Buchan, A.M., 1992. Immediate or delayed mild hypothermia prevents focal cerebral infarction. Brain Res. 587, 66-72.
59. Xue, D., Huang, Z.-G., Barnes, K., Lesiuk, H.J., Smith, K.E., Buchan, A.M., 1994. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. 14, 251-261.
60. Yatsugi, S., Takahashi, M., Kawasaki-Yatsugi, S., Koshiya, K., Sakamoto, S., Uematsu, D., Shimizu-Sasamata, M., 1996. Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. 16, 959-966.
61. Zorumski, C.F., Yamada, K.A., Price, M.T., Olney, J.T., 1993. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron 10, 61-67.